UNLABELLED: Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells. METHODS: Cell proliferation was determined using the sulphorodamine B cytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis. RESULTS: Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in human MCF-7 breast cancer cells. CONCLUSION: STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation.
UNLABELLED: Little is known about the interaction of novel anticancer drugs with other treatment modalities. THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells. METHODS: Cell proliferation was determined using the sulphorodamine Bcytotoxicity assay. Cell cycle analysis was performed with flow cytometry. Apoptosis was determined using a commercial cell death ELISA plus kit. Phosphorylated AKT, which has been suggested to be involved in radiation resistance, was detected by Western blot analysis. RESULTS: Exposure of SKNMC cells to STI-571 resulted in a dose-dependent antiproliferative effect and a decrease in phosphorylated AKT expression. There was no evidence of apoptosis. The combination of STI-571 with radiation or cisplatin had an additive antiproliferative effect in SKNMC cells (60% reduction in cell number). A similar effect was observed in humanMCF-7 breast cancer cells. CONCLUSION:STI-571 improves the outcome of cisplatin or irradiation treatment in vitro. AKT pathway may play a role in the additive effect of STI-571 and irradiation.
Authors: Michael J Pishvaian; Rebecca Slack; Eunice Y Koh; Jan H Beumer; Marion L Hartley; Ion Cotarla; John Deeken; Aiwu Ruth He; Jimmy Hwang; Shakun Malik; Kashif Firozvi; Minetta Liu; Beth Elston; Sandy Strychor; Merrill J Egorin; John L Marshall Journal: Cancer Chemother Pharmacol Date: 2012-09-27 Impact factor: 3.333
Authors: Nellie K McDaniel; Mari Iida; Kwangok P Nickel; Colin A Longhurst; Samantha R Fischbach; Tamara S Rodems; Carlene A Kranjac; Amber Y Bo; Qianyun Luo; Meghan M Gallagher; Noah B Welke; Kaitlyn R Mitchell; Alison E Schulz; Jaimee C Eckers; Rong Hu; Ravi Salgia; Seungpyo Hong; Justine Y Bruce; Randall J Kimple; Deric L Wheeler Journal: Clin Cancer Res Date: 2020-05-21 Impact factor: 12.531
Authors: Joaquim Soares do Brito; Miguel Esperança-Martins; André Abrunhosa-Branquinho; Cecilia Melo-Alvim; Raquel Lopes-Brás; João Janeiro; Dolores Lopez-Presa; Isabel Fernandes; José Portela; Luis Costa Journal: Cancers (Basel) Date: 2022-05-22 Impact factor: 6.575
Authors: Marion T Weigel; Linda Dahmke; Christian Schem; Dirk O Bauerschlag; Katrin Weber; Peter Niehoff; Maret Bauer; Alexander Strauss; Walter Jonat; Nicolai Maass; Christoph Mundhenke Journal: BMC Cancer Date: 2010-08-09 Impact factor: 4.430
Authors: Boling Qiao; Martin Kerr; Blaz Groselj; Mark T W Teo; Margaret A Knowles; Robert G Bristow; Roger M Phillips; Anne E Kiltie Journal: Cancer Res Date: 2013-01-09 Impact factor: 12.701